Trial Profile
Phase II trial of ofatumumab, dexamethasone and lenalidomide followed by randomisation to lenalidomide maintenance versus no further treatment for high-risk CLL (NCRI CLL210)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone; Ofatumumab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms CLL210 (CamDexRev)
- 07 Jun 2019 Status changed from recruiting to completed.
- 12 Nov 2015 Accrual to date is 100% according to United Kingdom Clinical Research Network.
- 12 Nov 2015 Planned End Date changed from 30 Sep 2015 to 31 Oct 2015, according to United Kingdom Clinical Research Network.